Program in Child Health Evaluative Sciences, The Hospital for Sick Children, Peter Gilgan Centre for Research and Learning, 686 Bay Street, Toronto, Ontario, M5G 0A4, Canada.
Department of Pharmacy, The Hospital for Sick Children555 University Avenue, Toronto, Ontario, M5G 1X8, Canada.
BMC Cancer. 2022 Jul 4;22(1):730. doi: 10.1186/s12885-022-09814-8.
Symptom Screening in Pediatrics Tool (SSPedi) was developed for symptom screening by children 8-18 years. Objectives were to evaluate the reliability and validity of proxy-SSPedi and self-report mini-SSPedi for younger children.
This multi-center study enrolled guardians of children 2-7 years receiving cancer treatments (proxy-SSPedi) and their children 4-7 years (mini-SSPedi). The two populations were: (1) More symptomatic group where children were receiving active cancer treatment and were in hospital or clinic for four consecutive days; and (2) Less symptomatic group where children were receiving maintenance therapy for acute lymphoblastic leukemia or had completed cancer therapy. Proxy-SSPedi or mini-SSPedi were completed with measures of mucositis, nausea, pain, quality of life and overall symptoms. Respondents in the more symptomatic group repeated proxy-SSPedi/mini-SSPedi and a global symptom change scale 3 days later.
There were 402 guardians and 326 children included in the analysis. Test re-test reliability of proxy-SSPedi showed intraclass correlation coefficient (ICC) 0.83 (95% confidence interval (CI) 0.72-0.90). Mean difference in proxy-SSPedi between more and less symptomatic groups was 9.7 (95% CI 8.3-11.1). Proxy-SSPedi was responsive to change and hypothesized relationships between measures were observed. With a priori threshold ≥0.6, inter-rater ICC among all dyads and those 6-7 years were 0.54 (95% CI 0.45-0.62) and 0.62 (95% CI 0.50-0.71) respectively. Among participating children, other hypothesized reliability and validity thresholds were generally met.
Proxy-SSPedi is reliable, valid and responsive in children 2-7 years old receiving cancer treatments. Mini-SSPedi can be used for children 6-7 years of age.
儿童症状筛查工具（SSPedi）专为 8-18 岁儿童设计，用于症状筛查。目的是评估代理-SSPedi 和自我报告迷你-SSPedi 在年幼儿童中的可靠性和有效性。
这项多中心研究招募了正在接受癌症治疗的 2-7 岁儿童的监护人（代理-SSPedi）及其 4-7 岁儿童（迷你-SSPedi）。这两个群体是：（1）症状更多的群体，其中儿童正在接受积极的癌症治疗，并且连续四天在医院或诊所；（2）症状较少的群体，其中儿童正在接受急性淋巴细胞白血病的维持治疗或已完成癌症治疗。代理-SSPedi 或迷你-SSPedi 与口腔粘膜炎、恶心、疼痛、生活质量和整体症状的测量值一起完成。症状更多的组中的受访者在 3 天后重复代理-SSPedi/迷你-SSPedi 和整体症状变化量表。
共有 402 名监护人和 326 名儿童纳入分析。代理-SSPedi 的测试重测可靠性显示组内相关系数（ICC）为 0.83（95%置信区间（CI）0.72-0.90）。症状更多和更少的群体之间代理-SSPedi 的平均差异为 9.7（95%CI 8.3-11.1）。代理-SSPedi 对变化敏感，并且观察到了与假设测量之间的关系。在预设阈值≥0.6 的情况下，所有对子和 6-7 岁儿童的组间 ICC 分别为 0.54（95%CI 0.45-0.62）和 0.62（95%CI 0.50-0.71）。在参与的儿童中，其他假设的可靠性和有效性阈值通常得到满足。
在接受癌症治疗的 2-7 岁儿童中，代理-SSPedi 具有可靠性、有效性和敏感性。迷你-SSPedi 可用于 6-7 岁儿童。
